In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming ...

AbbVie Inc. is challenging the Trump administration’s decision to select its Botox drug for a government program that slashes ...

AbbVie sues HHS over Botox Medicare pricing, challenging CMS authority under the Inflation Reduction Act and drug price negotiation rules.

Add Yahoo as a preferred source to see more of our stories on Google. President Donald Trump and the Centers for Medicare & Medicaid Services (CMS) recently announced the 15 drugs whose prices they ...

AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a plasma-derived product.

The selected medications treat a range of conditions, including cancer, psoriatic arthritis, and human immunodeficiency virus type 1 infection.

Fifteen prescription medications, including Botox and the diabetes drug Trulicity, will be the focus of federal price negotiations that could lower prices for Medicare patients. An outgrowth of the ...

Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare. The Centers for Medicare & Medicaid Services (CMS), the federal agency that ...

The Trump administration on Tuesday announced the next round of prescription drugs up for Medicare price negotiations. The list includes Botox and the GLP-1 drug Trulicity. The negotiations stem from ...

By Jonathan Stempel Feb 11 (Reuters) - AbbVie sued the U.S. Department of Health and Human Services on Wednesday, challenging ...

The list covers the top 15 highest spending drugs for Medicare across a variety of serious health conditions. HealthDay News — Fifteen prescription medications, including Botox and the diabetes drug ...